Investigational Medication for people with Relapsing Remitting Multiple Sclerosis

27-month study evaluating the efficacy and safety of ofatumumab, given as an injection under the skin once a month, versus Aubajio, an oral medication approved for patients with MS. After the blinded study, patients that completed treatment will be given the opportunity to enter an extension trial.

  • Ages 18-55
  • Subjects must have at least one relapse in the past year or two over the past two years